journal article Open Access Nov 01, 2017

Desoxycorticosterone Pivalate Duration of Action and Individualized Dosing Intervals in Dogs with Primary Hypoadrenocorticism

View at Publisher Save 10.1111/jvim.14828
Abstract
Abstract

Background
Clinicians alter dosing for desoxycorticosterone pivalate (DOCP) to mitigate costs, but this practice has not been critically evaluated in a prospective clinical trial.


Hypothesis/Objectives
The duration of action of DOCP is longer than 30 days in dogs with primary hypoadrenocorticism (PH).


Animals
A total of 53 client-owned dogs with PH. Twenty-four dogs with newly diagnosed PH (Group 1) and 29 dogs with treated PH (Group 2).


Methods
Prospective, multicenter, clinical trial. For phase I, DOCP was administered and plasma sodium and potassium concentrations were measured until the dog developed hyponatremia or hyperkalemia at a planned evaluation, or displayed clinical signs with plasma electrolyte concentrations outside of the reference interval independent of a planned evaluation, thus defining DOCP duration of action. Plasma electrolyte concentrations then were assessed at the end of the individualized dosing interval (IDI; i.e., DOCP duration of action minus 7 days, phase II and at least 3 months after concluding phase II, phase III).


Results
The duration of action of DOCP in dogs in phase I with naïve PH (n = 24) ranged from 32 to 94 days (median, 62 days; 95% confidence interval [CI], 57, 65) and previously treated PH (n = 29) from 41 to 124 days (median, 67 days; CI, 56, 72). Overall, the final DOCP dosing interval for all dogs that completed phase II (n = 36) ranged from 38 days to 90 days (median, 58 days; CI, 53, 61). No dog that completed phase III (n = 15) required reduction in the IDI. The DOCP duration of action, independent of group, was not significantly associated with several baseline variables. The median drug cost reduction using IDI was approximately 57.5% per year.


Conclusion and Clinical Importance
The duration of action of DOCP in dogs with PH is >30 days, and plasma sodium and potassium concentrations can be maintained with an IDI >30 days long term.
Topics

No keywords indexed for this article. Browse by subject →

References
23
[1]
Scott-Moncrieff "Canine and Feline Endocrinology" (2015)
[2]
Van Lanen "Canine hypoadrenocorticism: Pathogenesis, diagnosis, and treatment" Top Companion Anim Med (2014) 10.1053/j.tcam.2014.10.001
[3]
Kintzer "Treatment and long-term follow-up of 205 dogs with hypoadrenocorticism" J Vet Intern Med (1997) 10.1111/j.1939-1676.1997.tb00072.x
[4]
Incidence, Severity and Prognosis Associated with Hyponatremia in Dogs and Cats

Y. Ueda, K. Hopper, S.E. Epstein

Journal of Veterinary Internal Medicine 2015 10.1111/jvim.12581
[5]
Riordan "Small Animal Critical Care Medicine" (2015)
[6]
Church "Small Animal Clinical Pharmacology" (2008)
[7]
Efficacy of microcrystalline desoxycorticosterone pivalate for treatment of hypoadrenocorticism in dogs

Randy C. Lynn, Edward C. Feldman, Richard W. Nelson et al.

Journal of the American Veterinary Medical Associa... 1993 10.2460/javma.1993.202.03.392
[8]
Lynn "Treatment of canine hypoadrenocorticism with microcrystalline desoxycorticosterone pivalate" Br Vet J (1991) 10.1016/0007-1935(91)90091-z
[9]
Shiah "Diagnostic value of plasma aldosterone/potassium ratio in hypoaldosteronism" J Formos Med Assoc (1995)
[10]
Oelkers "Diagnosis and therapy surveillance in Addison's disease: Rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone" J Clin Endocrinol Metab (1992)
[11]
Baumstark "Evaluation of aldosterone concentrations in dogs with hypoadrenocorticism" J Vet Intern Med (2014) 10.1111/jvim.12243
[12]
Dibartola "Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice" (2012)
[13]
Harrop "Studies on the Suprarenal Cortex. IV. The effect of sodium salts in sustaining the suprarenalectomized dog" J Exp Med (1935) 10.1084/jem.61.6.839
[14]
Quinkler "Mineralocorticoid substitution and monitoring in primary adrenal insufficiency" Best Pract Res Clin Endocrinol Metab (2015) 10.1016/j.beem.2014.08.008
[15]
Oelkers "Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement" Klin Wochenschr (1976) 10.1007/bf01469025
[16]
Flad "The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency" Clin Endocrinol (Oxf) (1996) 10.1046/j.1365-2265.1996.00838.x
[17]
Baumstark "Use of plasma renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: Desoxycorticosterone versus fludrocortisone" J Vet Intern Med (2014) 10.1111/jvim.12426
[18]
Smith "Evidence that patients with Addison's Disease are undertreated with fludrocortisone" Lancet (1984) 10.1016/s0140-6736(84)90181-8
[19]
Klein "Canine hypoadrenocorticism: Part II" Can Vet J (2010)
[20]
Schaer "The treatment of acute adrenocortical insufficiency in the dog" J Vet Emerg Crit Care (2001) 10.1111/j.1476-4431.2001.tb00058.x
[21]
Tsai "Life-threatening hypokalemia in an asthmatic patient treated with high dose hydrocortisone" Am J Med Sci (2004) 10.1097/00000441-200403000-00007
[22]
Kratochwil "Predicting plasma protein binding of drugs: A new approach" Biochem Pharmacol (2002) 10.1016/s0006-2952(02)01074-2
[23]
"Desoxycorticosterone pivalate"
Metrics
21
Citations
23
References
Details
Published
Nov 01, 2017
Vol/Issue
31(6)
Pages
1649-1657
License
View
Cite This Article
J.A. Jaffey, P. Nurre, A.B. Cannon, et al. (2017). Desoxycorticosterone Pivalate Duration of Action and Individualized Dosing Intervals in Dogs with Primary Hypoadrenocorticism. Journal of Veterinary Internal Medicine, 31(6), 1649-1657. https://doi.org/10.1111/jvim.14828